Biote Price to Free Cash Flow Ratio 2021-2024 | BTMD

Biote price to free cash flow ratio from 2021 to 2024. Price to free cash flow ratio can be defined as

Biote Price to Free Cash Flow Ratio 2021-2024 | BTMD

Biote price to free cash flow ratio from 2021 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$202.6B
Stryker (SYK)$144.4B
Boston Scientific (BSX)$130.4B
Medtronic (MDT)$113.2B
EssilorLuxottica (ESLOY)$112.1B
Lonza Group Ag (LZAGY)$45.3B
Haleon (HLN)$43B
GE HealthCare Technologies (GEHC)$39B
ResMed (RMD)$36.5B
Terumo (TRUMY)$30.6B
Koninklijke Philips (PHG)$24.9B
Zimmer Biomet Holdings (ZBH)$21.8B
Insulet (PODD)$19.3B
Baxter (BAX)$17.5B
Smith & Nephew SNATS (SNN)$10.8B
Bio-Rad Laboratories (BIO)$10.2B
BellRing Brands (BRBR)$9.2B
Demant (WILYY)$8.4B
Lantheus Holdings (LNTH)$5.8B
TG Therapeutics (TGTX)$4.8B
Haemonetics (HAE)$4.6B
ICU Medical (ICUI)$4.4B
Prestige Consumer Healthcare (PBH)$4B
Perrigo (PRGO)$3.6B
Envista Holdings (NVST)$3.6B
Neogen (NEOG)$3.6B
Agios Pharmaceuticals (AGIO)$3.4B
GN Store Nord (GNNDY)$3.1B
Shandong Weigao Medical Polymer (SHWGF)$3B
QuidelOrtho (QDEL)$2.9B